AXXE Sets Sights On OTC QB Status And Sets Course For Strong Revenue Growth
Good Afternoon!
AXXE is on display today because the company has presented itself with a chance for very strong upside opportunity to traders – provided you act now, of course.
Powering the company is a couple of important events:
-
AXXE recently announced anticipated uplisting to the OTC QB. This doesn’t surprise me, not least because the company has been delivering strong growth and expansion numbers since last year. Audits are expected to be completed within the next 30 days.
-
The company has been making a few spectacular partnership deals, including becoming the official fitness and training partner of WWE (Worldwide Wrestling Entertainment)
These combined with longstanding sales growth has created the perfect storm for a potential breakout.
On the technical side AXXE has been building momentum and daily volatility is now rising in line with this surge in interest.
The play remains accessible at around 2 cents a share, currently. Pair that with the 12-month high of 27 cents and you see why the latest round of news could be the spark that allows AXXE to catch fire.
Start some research into AXXE right away.
AXXE Must-See Technicals
AXXE has 29.33 million shares in the public float which is low compared to the industry average.
AXXE is trading with a 50 DMA of 0.05 which suggests potential undervaluation over the short term of 150%.
AXXE is currently oversold and has a RSI of 37. Bounce potential from current levels is very strong.
AXXE is anticipating uplisting to the OTC QB which will be a major boost for its investing profile. Expect Wall Street to give this play a more serious look.
The 4-week high for AXXE is 0.05. This level could come under a serious test shortly given the rising volatility of the play.
AXXE delivered 60% intraday gains on March 17 after it opened at 0.10 and rallied to a high of 0.16
About
AXXE (Axxess Pharma Inc.) is a pharmaceutical company which engages in the marketing and distribution of various pharmaceutical products and diagnostic medical devices in Canada and internationally.
AXXE distributes dermatological, therapeutic nutritional, pain management, and diagnostic products.
AXXE’s is a licensee for the TapouT brand and the company has been distributing its own Tapout-branded line of muscle supplements and pain relief supplements.
AXXE distributes its products through physicians, hospitals, government and defense institutions, and pharmacies. The company was founded in 1997 and is headquartered in Markham, Canada.
Nutritional Supllemnts Set To Hit $60 Billion By 2021
AXXE is one of a few companies laying the strategic foundation to reap the benefits of the exploding nutritional supplements industry.
The nutritional supplements industry produced about $32 billion in 2012 and the Nutritional Business Journal estimates that the market will reach $60 billion by 2021.
Big News Development
Axxess Pharma Prepares for Strong Revenue Growth in 2nd Half of 2015 -- Fueled by Their Latest Line of Tapout Products and Up-Listing to the OTCQB Stock Exchange
Financial Audits to Be Completed and Submitted to FINRA Within 30 Days
AXXE is on the move and has just announced that management projects a strong finish to the second half of 2015.
According to this release, 2015 has been a year of aggressive marketing and global approvals to sell their all-natural Tapout supplements. Axxess Pharma is also proud to be a licensee for Tapout, the official fitness and training partner of WWE (Worldwide Wrestling Entertainment).
AXXE anticipates audits will be completed within the next 30 days. Once audits are complete, management anticipates a quick up-listing to the OTCQB.
To learn more about AXXE please visit their website: http://www.axxesspharmainc.com/
AXXE is a company that has bided its time well. The strong move to 27 cents on the year is a strong sign that it could turn the corner soon.
Recent rallies have delivered gains of up to 60% in one day so don’t hesitate to make your move now.
